John Cush’s Post

Romosozumab vs. Teriparatide in Postmenopausal Osteoporosis The effectiveness/safety of ROMO and TPTD were compared in a clinical setting, and ROMO showed greater increases in BMD than TPTD after 12 months of therapy, along with a higher completion rate. https://buff.ly/4djC7Nq

Treatment Regimen Considerations: Panelists discuss how various patient characteristics, including age, fitness level, cytogenetic risk, and comorbidities, influence their decision to use more intensive quadruplet regimens like D-VRd (daratumumab plus bortezomib, lenalidomide, and dexamethasone) vs standard triplet regimens, such as VRd or KRd (carfilzomib, lenalidomide, and dexamethasone) in transplant-eligible multiple myeloma patients, while also considering administration logistics and supportive care requirements #finance #pharmacy #lifesciences

Semaglutide treatment for 24 weeks resulted in a clinically meaningful reduction in albuminuria in patients with overweight/obesity and non-diabetic CKD. There was also reduction in BP, hsCRP and NT-proBNP. https://lnkd.in/eAnCuAcj

In this clip from our recent pearl, discover how intensive atorvastatin therapy improves endothelial function and reduces inflammation in STEMI patients undergoing primary PCI. Dive into the 2016 study by Xu X, Liu Y, Li K, et al. Visit our website to learn more. #PharmacyPearls #EmergencyMedicine #Statins #STEMI #Atorvastatin #PrimaryPCI

🫘 𝑫𝒓𝒖𝒈 𝒊𝒏𝒅𝒖𝒄𝒆𝒅 𝑲𝒊𝒅𝒏𝒆𝒚 𝑫𝒂𝒎𝒂𝒈𝒆 🫘 💡 Did you know? 𝑴𝒆𝒅𝒊𝒄𝒂𝒕𝒊𝒐𝒏𝒔 are among the leading causes of acute kidney injury (AKI), accounting for nearly 25% of cases in hospitalized patients, especially in critical care settings. 🔍 Interestingly, some drugs cause pseudo-nephrotoxicity—an increase in serum creatinine without true renal damage. Examples include: 💊 Trimethoprim 💊 Cimetidine 💊 Certain Cephalosporins 📊 A Contemporary Classification of DIKD: 1️⃣ Dysfunction without Damage: Drugs affect systemic or intraglomerular hemodynamics without direct injury. 2️⃣ Damage without Dysfunction: Glomerular, tubular, or interstitial damage without immediate functional decline. 3️⃣ Dysfunction with Damage: Combined hemodynamic and structural injury. 💬 Have you encountered any medications causing AKI in your practice? Share your experience in the comments! 🔗 Reference: Moving Toward a Contemporary Classification of Drug-Induced Kidney Disease https://lnkd.in/d9jK3JkZ #InternalMedicine #Nephrology #ClinicalPharmacy #InternalMedicine_GS_Nephrology

⚔️ 𝗣𝘀𝗲𝘂𝗱𝗼-𝗻𝗲𝗽𝗵𝗿𝗼𝘁𝗼𝘅𝗶𝗰𝗶𝘁𝘆 refers to a false impression of kidney damage or impaired renal function 𝗰𝗮𝘂𝘀𝗲𝗱 𝗯𝘆 𝗱𝗿𝘂𝗴-𝗶𝗻𝗱𝘂𝗰𝗲𝗱 𝗰𝗵𝗮𝗻𝗴𝗲𝘀 in laboratory markers like serum creatinine (SCr) or blood urea nitrogen (BUN), 𝘄𝗶𝘁𝗵𝗼𝘂𝘁 𝗮𝗻𝘆 𝗮𝗰𝘁𝘂𝗮𝗹 𝗸𝗶𝗱𝗻𝗲𝘆 𝗶𝗻𝗷𝘂𝗿𝘆. ✨ This phenomenon is due to the effect of certain drugs on renal physiology or interference with laboratory assays rather than direct nephrotoxic effects. ✅ 𝙄𝙣𝙘𝙧𝙚𝙖𝙨𝙚𝙙 𝙎𝙚𝙧𝙪𝙢 𝘾𝙧𝙚𝙖𝙩𝙞𝙣𝙞𝙣𝙚 𝙒𝙞𝙩𝙝𝙤𝙪𝙩 𝘼𝙘𝙩𝙪𝙖𝙡 𝘿𝙖𝙢𝙖𝙜𝙚: - Trimethoprim: Inhibits tubular secretion of creatinine. - Cimetidine: Similar mechanism as trimethoprim. - Probenecid: Reduces creatinine clearance. ✅ 𝙄𝙣𝙩𝙚𝙧𝙛𝙚𝙧𝙚𝙣𝙘𝙚 𝙬𝙞𝙩𝙝 𝙇𝙖𝙗𝙤𝙧𝙖𝙩𝙤𝙧𝙮 𝘼𝙨𝙨𝙖𝙮𝙨: Cephalosporins (e.g., cefoxitin): Interfere with creatinine assays, falsely elevating serum creatinine values. ✅ 𝙄𝙣𝙘𝙧𝙚𝙖𝙨𝙚 𝙞𝙣 𝘽𝙡𝙤𝙤𝙙 𝙐𝙧𝙚𝙖 𝙉𝙞𝙩𝙧𝙤𝙜𝙚𝙣 (𝘽𝙐𝙉): Corticosteroids or High-Protein Diet: Enhance protein metabolism, increasing BUN levels without renal injury. ✨ Understanding pseudo-nephrotoxicity is crucial to avoid unnecessary discontinuation of essential medications or inappropriate interventions. #kidney #AKI #renal #pharmacology #pharmacist #صيدلي 

Tenapanor as Therapy for Hyperphosphatemia in Maintenance Dialysis Patients: Results from the OPTIMIZE Study This study shows tenapanor as monotherapy or in combination with PBs effectively lowered serum phosphate toward the target range Kidney360 5(5):p 732-742, May 2024 DOI: 10.34067/KID.0000000000000387

Colchicine has shown promising results in reducing coronary artery plaque and associated risks. Clinical studies indicate a 30% reduction in death after a #heartattack for patients taking 0.5mg of colchicine daily, with minimal side effects such as diarrhea. This anti-inflammatory drug works by reducing macrophage activity in #plaque and can be effectively combined with statins. To learn more: https://lnkd.in/dbvcbti7

New target trial emulation from Kyoto University compares #denosumab to oral bisphosphonates for dialysis patients. Trial found 45% decrease in fracture risk, 36% increase in #MACE risk. Authors caution that results need to be confirmed with future research. https://bit.ly/3WaeBMk

Intellia's Nex-z shows early promise with strong biomarker benefits in ATTR amyloidosis (https://lnkd.in/eeSfk2GG).